Nanotech

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Quebec Virtual Investor Conference on March 30 th and 31 st .  This virtual event will showcase live company presentations and interactive discussions focused on disruptive technologies and investing in Quebec's critical and strategic minerals and high-tech sectors.

Individual investors, institutional investors, advisors, and analysts are invited to attend.

REGISTER NOW AT: https://bit.ly/36oj3zW

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations and schedule 1x1 meetings.

NEW CONFERENCE FEATURE: Ability to schedule 1x1 meetings with presenting companies' management.

"We are thrilled to host the two-day Quebec Critical Metals and Technology Investor conference, highlighting the breadth of the province's rich commodities and burgeoning technology," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group.  We graciously welcome the participation of Quebec's Delegate General, Martine Hebert and Associate Deputy Minister of Mines, Nathalie Camden to this signature event."

"On behalf of the Quebec Government, I am delighted to take part in "Investing in Quebec's Critical and Strategic Minerals and High-Tech Sectors Conference." This conference will showcase for U.S. and investors elsewhere some our best competitive advantages : all the minerals and raw materials required for battery manufacturing and a vast territory containing new mining opportunities with a reliable, sustainable and ethical partner," said Nathalie Camden, Associate Deputy Minister of Mines. "Our action plan on critical and strategic minerals has already yielded impressive results, not only because we have the resources, the will and the tools needed, but because we ensure that all agencies and government entities work together toward one main goal: helping companies and governments to secure their mineral supply chain. We are thankful to the New York Delegate General, Martine Hebert and her team for the opportunity and their partners OTC Markets, Murdock Capital Partners and TAA Advisory for this remarkable event."

Wednesday March 30th Agenda:

Eastern
Time (ET)
Presentation Ticker(s)
9:30 AM Introduction: Martine Hebert, New York Delegate General Government of Quebec
9:35 AM Welcome Remarks: Nathalie Camden, Associate Deputy Minister of Mines of Quebec
9:45 AM Panel: Key Factors to Consider in Mining Investment Decisions:

Moderated by Investment Quebec
10:30 AM Azimut Exploration Pink: AZMTF |TSXV: AZM
11:00 AM Voyager Metals Inc. Pink: VDMRF | TSXV: VONE
11:30 AM QC Copper & Gold Inc. OTCQB: QCCUF | TSXV: QCCU
12:00 PM Québec Nickel Corp. OTCQB: QNICF | CSE: QNI
12:30 PM Vision Lithium OTCQB: ABEPF | TSXV: VLI
1:00 PM Focus Graphite Inc. OTCQB: FCSMF | TSXV: FMS
1:30 PM Critical Elements Lithium Corp OTCQX: CRECF | TSXV: CRE
2:00 PM St-Georges Éco-Mining Corp OTCQB: SXOOF | CSE: SX
2:30 PM Lomiko Metals Inc. OTCQB: LMRMF | TSXV: LMR
3:00 PM Patriot Battery Metals Inc. OTCQB: PMETF | CSE: PMET
3:30 PM Commerce Resources Corp. OTCQX: CMRZF | TSXV: CCE
4:00 PM NanoXplore Inc. OTCQX: NNXPF | TSX: GRA

Thursday March 31st Agenda:

Eastern
Time (ET)
Presentation Ticker(s)
9:30 AM Panel: A Partnership for a Turnaround of a Lithium Mine in Quebec with Sayona Piedmont

Moderated by Investment Quebec
Nasdaq: PLL and OTCQB: SYAXF
10:00 AM Doré Copper Mining Corp. OTCQX: DRCMF | TSXV: DCMC
10:30 AM Orford Mining Corp. Pink: ORMFF | TSXV: ORM
11:00 AM Imperial Mining Group OTCQB: IMPNF | TSXV: IPG
11:30 AM Geomega Resources Inc. OTCQB: GOMRF | TSXV: GMA
12:00 PM Panel: Quebec 360 Degrees: From Mining to Recycling Batteries with Nouveau Monde Graphite, Lithion Recycling, & Blue Solutions

Moderated by Investment Quebec
1:00 PM Tekna Holdings AS FRA: 8VB | OSE: TEKNA
1:30 PM HPQ-Silicon Resources Inc. OTCQX: HPQFF | TSXV: HPQ
2:30 PM Renforth Resources Inc. OTCQB: RFHRF | CSE: RFR
3:00 PM VanadiumCorp Resource Inc. Pink: VRBFF | TSXV: VRB

To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit
www.virtualinvestorconferences.com .

About Virtual Investor Conferences ®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

Media Contact:
OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

Virtual Investor Conferences Contact:
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GRA:CA,NNXPF
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors

Strong financial position provides cash runway through 2028; cash, cash equivalents and marketable securities of $703.8 million as of June 30, 2022

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Company prioritizes NUV-868, its BD2 selective BET inhibitor currently in a Phase 1 dose escalation study in advanced solid tumors, and its novel small molecule Drug-Drug Conjugate (DDC) platform

Company restructuring and cost savings associated with NUV-422 program discontinuation to extend cash runway through 2028

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Dr. Liu is a clinical leader who brings expertise in the discovery, development, and regulatory approval of oncology therapies worldwide

Ms. Wentworth has over two decades of industry experience in domestic and international regulatory and quality affairs

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Top 6 Nanotechnology Uses

Top 6 Nanotechnology Uses

While there’s been plenty of focus on apps and cloud computing in the technology space, advances are also being made in hardware-focused sectors such as nanotechnology.

Nanotechnology uses include everything from safer food processing to more efficient drug-delivery systems to tiny transistors that allow for smaller, more powerful computer chips. Unsurprisingly, nanotechnology applications are set to grow significantly in the coming years. The global nanotechnology market is projected to reach US$70.7 billion by 2026, growing at a compound annual growth rate of 9.2 percent between 2020 and 2026.

Still, for investors just starting to look at nanotechnology stocks, it can be difficult to know where to begin as nanotechnology applications are so varied. As a starting point, here’s an overview of six of the top areas in which nanoscience and nanotechnologies are making a big difference today.

Keep reading...Show less

NanoXplore Announces Management and Board Changes

NanoXplore Inc. (" NanoXplore " or the " Company ") (TSX: GRA and OTCQX: NNXPF) announces today that after more than eight years with NanoXplore, Luc Veilleux, CFO, will be departing the Company from his position on July 18, 2022 and will be joining VoltaXplore as CFO. He will remain with the Corporation until September 1, 2022 to ensure a smooth transition. Luc has over 25 years of executive management, financial and operational experience in manufacturing and mining industries. His previous roles include CFO of Mason Graphite, President of Maxi Canada, and CFO of Imerys Graphite and Carbon. Mr. Veilleux, with his work ethic and talent, made a major contribution to NanoXplore's development.

"On behalf of everyone at NanoXplore, I'd like to express my gratitude to Luc for his outstanding leadership, selfless partnership, and financial stewardship. Luc has played a crucial role in NanoXplore's success and growth by helping lay the solid foundation that supports the company's innovation, global presence and financial strength. I am looking forward to continue working with Luc in VoltaXplore" said Soroush Nazarpour, President and CEO, NanoXplore.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company's Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The Company's Phase 1 trial began enrolling patients 19 months ago in December 2020 and, in recent months, was exploring higher doses to define a maximum tolerated dose. Following the emergence of uveitis, a form of inflammation in the eye, in certain patients receiving NUV-422, the Company proactively paused enrollment of new patients in order to further assess these adverse events with investigators and uveitis experts, and also reached out to the FDA for guidance around an appropriate path forward. While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study.

"We are committed to patient safety across all of our studies and to working collaboratively with the FDA to develop, as efficiently as possible, new medicines where existing therapies are inadequate," said David Hung, M.D., founder, president and chief executive officer of Nuvation Bio. "Based upon the recent development of uveitis as a potential safety signal, we will conduct an overall risk/benefit analysis of the NUV-422 program. Our goal is always to ensure that we deploy our resources on programs that have the highest probability of success and of generating value for patients and our investors. With $737.7 million in cash as of March 31, 2022, we are well positioned to continue developing all of our internal product candidates.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×